Axsome to narrow focus of depression drug trial after limited success in initial run
Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...
Why Shares of Axsome Therapeutics Slumped Today
Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...
Fierce Pharma3d
Axsome's Sunosi comes up short in trial but shows promise in treating MDD with daytime sleepiness
A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
The Pharma Letter1d
Axsome to battle on with solriamfetol despite mixed data
CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...
Axsome slips as late-stage trial for depression therapy fails
Axsome Therapeutics (AXSM) stock falls as its depression drug solriamfetol fails in a Phase 3 trial for those with daytime ...
2AXSM : Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows...
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...
Axsome Must Face Securities Fraud Suit Over Migraine Drug Delays
Axsome Therapeutics Inc. investors can proceed with a proposed class action alleging the drugmaker misled them about a ...
Needham & Company LLC Reiterates “Buy” Rating for Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...
Axsome succeeds in late-stage trial for ADHD therapy
Axsome Therapeutics (AXSM) stock gains as solriamfetol, its experimental drug for ADHD succeeds in a Phase 3 trial. Read more ...
Fierce Pharma10d
Axsome touts success of phase 3 trial of Sunosi in ADHD, adding to 'string of recent wins'
Taking a gamble by purchasing the rights to an underperforming narcolepsy drug may soon begin paying dividends for Axsome ...
Axsome selloff on study miss should be ‘contained,’ says Mizuho
Mizuho says that in a “relative disappointment,” the results from Axsome Therapeutics (AXSM)’ Phase 3 PARADIGM study data for solriamfetol in ...
Axsome shares fall after trial results disappoint
In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...